JP2019524889A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524889A5 JP2019524889A5 JP2019530368A JP2019530368A JP2019524889A5 JP 2019524889 A5 JP2019524889 A5 JP 2019524889A5 JP 2019530368 A JP2019530368 A JP 2019530368A JP 2019530368 A JP2019530368 A JP 2019530368A JP 2019524889 A5 JP2019524889 A5 JP 2019524889A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- composition according
- effective amount
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 16
- 239000000651 prodrug Substances 0.000 claims description 10
- 229940002612 prodrug Drugs 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 210000001789 adipocyte Anatomy 0.000 claims description 4
- 210000000577 adipose tissue Anatomy 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 102000011690 Adiponectin Human genes 0.000 claims description 3
- 108010076365 Adiponectin Proteins 0.000 claims description 3
- 206010065687 Bone loss Diseases 0.000 claims description 3
- 210000000963 osteoblast Anatomy 0.000 claims description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 230000008468 bone growth Effects 0.000 claims description 2
- 230000003442 weekly effect Effects 0.000 claims description 2
- 230000002354 daily effect Effects 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 230000001582 osteoblastic effect Effects 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022090843A JP2022116294A (ja) | 2016-08-18 | 2022-06-03 | 骨疾患の治療のためのＰＰＡＲγアゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376732P | 2016-08-18 | 2016-08-18 | |
| US62/376,732 | 2016-08-18 | ||
| PCT/US2017/047584 WO2018035449A1 (en) | 2016-08-18 | 2017-08-18 | Pparϒ agonist for treatment of bone disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022090843A Division JP2022116294A (ja) | 2016-08-18 | 2022-06-03 | 骨疾患の治療のためのＰＰＡＲγアゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019524889A JP2019524889A (ja) | 2019-09-05 |
| JP2019524889A5 true JP2019524889A5 (enExample) | 2020-10-01 |
Family
ID=61197122
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019530368A Pending JP2019524889A (ja) | 2016-08-18 | 2017-08-18 | 骨疾患の治療のためのＰＰＡＲγアゴニスト |
| JP2022090843A Withdrawn JP2022116294A (ja) | 2016-08-18 | 2022-06-03 | 骨疾患の治療のためのＰＰＡＲγアゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022090843A Withdrawn JP2022116294A (ja) | 2016-08-18 | 2022-06-03 | 骨疾患の治療のためのＰＰＡＲγアゴニスト |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190167660A1 (enExample) |
| EP (1) | EP3500269A4 (enExample) |
| JP (2) | JP2019524889A (enExample) |
| KR (1) | KR20190065252A (enExample) |
| CN (1) | CN109843292A (enExample) |
| AU (1) | AU2017313842A1 (enExample) |
| BR (1) | BR112019003133A2 (enExample) |
| CA (1) | CA3033971A1 (enExample) |
| EA (1) | EA201990513A1 (enExample) |
| SG (2) | SG10202101500WA (enExample) |
| WO (1) | WO2018035449A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107683135A (zh) | 2015-03-09 | 2018-02-09 | 因特克林医疗有限公司 | 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法 |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| JP2024013883A (ja) * | 2022-07-21 | 2024-02-01 | 株式会社三洋物産 | 遊技機 |
| JP2024013885A (ja) * | 2022-07-21 | 2024-02-01 | 株式会社三洋物産 | 遊技機 |
| JP2024013886A (ja) * | 2022-07-21 | 2024-02-01 | 株式会社三洋物産 | 遊技機 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL357678A1 (en) * | 2000-04-28 | 2004-07-26 | Sankyo Company, Limited | Ppargamma modulators |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| CA2555914A1 (en) * | 2004-03-08 | 2005-09-22 | Amgen Inc. | Therapeutic modulation of ppar (gamma) activity |
| HK1218510A1 (zh) * | 2013-01-30 | 2017-02-24 | Intekrin Therapeutics, Inc. | 用於治療多發性硬化症的PPARγ激動劑 |
| PL3203999T3 (pl) * | 2014-10-10 | 2020-07-27 | Liminal Biosciences Limited | Podstawione związki aromatyczne i kompozycje farmaceutyczne do zapobiegania i leczenia osteoporozy |
-
2017
- 2017-08-18 KR KR1020197007605A patent/KR20190065252A/ko not_active Ceased
- 2017-08-18 EP EP17842205.1A patent/EP3500269A4/en not_active Withdrawn
- 2017-08-18 SG SG10202101500WA patent/SG10202101500WA/en unknown
- 2017-08-18 WO PCT/US2017/047584 patent/WO2018035449A1/en not_active Ceased
- 2017-08-18 SG SG11201901328VA patent/SG11201901328VA/en unknown
- 2017-08-18 CA CA3033971A patent/CA3033971A1/en active Pending
- 2017-08-18 JP JP2019530368A patent/JP2019524889A/ja active Pending
- 2017-08-18 EA EA201990513A patent/EA201990513A1/ru unknown
- 2017-08-18 AU AU2017313842A patent/AU2017313842A1/en not_active Abandoned
- 2017-08-18 BR BR112019003133-2A patent/BR112019003133A2/pt not_active IP Right Cessation
- 2017-08-18 CN CN201780063392.8A patent/CN109843292A/zh active Pending
- 2017-08-18 US US16/326,070 patent/US20190167660A1/en not_active Abandoned
-
2022
- 2022-06-03 JP JP2022090843A patent/JP2022116294A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240299381A1 (en) | Methods of administering elagolix | |
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| Jabbour et al. | Bisphosphonates inhibit bone remodeling in the jaw bones of rats and delay healing following tooth extractions | |
| MX2011007854A (es) | Metodos para tratar infartos agudos al miocardio y trastornos relacionados. | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| JP2015517493A5 (enExample) | ||
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| BR112014015482A2 (pt) | compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática | |
| JP2015505564A5 (enExample) | ||
| RU2016114098A (ru) | Новое производное аналога инсулина | |
| JP2022116294A (ja) | 骨疾患の治療のためのＰＰＡＲγアゴニスト | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| MX2021009539A (es) | Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
| JP2019507786A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| RU2020120156A (ru) | Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена | |
| JP2018536638A5 (enExample) | ||
| JP2023549849A5 (enExample) | ||
| JP2019529569A5 (enExample) | ||
| HRP20211661T1 (hr) | Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti | |
| JP2020505448A5 (enExample) | ||
| RU2013126798A (ru) | Комбинированная терапия дексаметазоном | |
| RU2015152175A (ru) | Комбинация ro5503781, капецитабина и оксалиплатина для терапии рака | |
| EA201992690A1 (ru) | Применение вибегрона для лечения гиперактивного мочевого пузыря | |
| ZA202201789B (en) | Solid oral dosage form comprising naproxen and vitamin b6 |